FDA Approval Summary: Belzutifan for VHL Disease Tumors-Response

Affiliations

¹ Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
² Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.

Comment

Jaleh Fallah et al. Clin Cancer Res. 2023.

. 2023 Feb 1;29(3):685.

doi: 10.1158/1078-0432.CCR-22-3428.

¹ Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
² Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.

No abstract available

Comment on

FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors.
Fallah J, Brave MH, Weinstock C, Mehta GU, Bradford D, Gittleman H, Bloomquist EW, Charlab R, Hamed SS, Miller CP, Dorff SE, Chambers WA, Mixter BD, Dinin J, Pierce WF, Ricks TK, Tang S, Donoghue M, Pazdur R, Amiri-Kordestani L, Ibrahim A, Beaver JA. Fallah J, et al. Clin Cancer Res. 2022 Nov 14;28(22):4843-4848. doi: 10.1158/1078-0432.CCR-22-1054. Clin Cancer Res. 2022. PMID: 35727604 Free PMC article.
FDA Approval Summary: Belzutifan for VHL Disease Tumors-Letter.
Trinh JQ, Ellithi M, Shonka N, Bergan RC. Trinh JQ, et al. Clin Cancer Res. 2023 Feb 1;29(3):684. doi: 10.1158/1078-0432.CCR-22-2968. Clin Cancer Res. 2023. PMID: 36722140 Free PMC article. No abstract available.